Combined modality therapy for oesophageal squamous cell carcinoma

Area of Science:

• Oncology
• Radiation Oncology
• Surgical Oncology

Background:

• Esophageal squamous cell carcinoma (ESCC) presents a significant challenge in cancer treatment.
• Combined modality treatments are explored to improve outcomes for ESCC patients.

Purpose of the Study:

• To evaluate the efficacy of radiation therapy combined with bleomycin or a retinoid in patients with ESCC.
• To assess the impact of subsequent surgery on survival rates in ESCC patients treated with neoadjuvant therapy.

Main Methods:

• A prospective study involving 110 patients diagnosed with ESCC.
• Patients received radiation therapy with either bleomycin or a retinoid.
• Surgical intervention was considered for a subset of patients post-irradiation.

Main Results:

• A significantly higher survival rate was observed in patients who underwent surgery compared to those who did not.
• The benefit of surgery was primarily attributed to patients who had a radical resection.
• The best outcomes were seen in patients who achieved a complete tumor response after preoperative therapy, with survival exceeding 71 months.

Conclusions:

• The combined radiation and chemotherapy/retinoid treatment showed limited curative potential as a standalone therapy for ESCC.
• More intensive preoperative treatment strategies and meticulous patient selection for surgery are crucial for improving treatment success in ESCC.
• Radical surgical resection following neoadjuvant therapy offers the most promising survival benefit for select ESCC patients.